Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells
Olivier Preynat-Seauve
Laboratory of Experimental Cell Therapy, Department of Genetic and Laboratory Medicine, Geneva University Hospital, Switzerland
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Switzerland
These authors contributed equally to this work.
Search for more papers by this authorCasimir de Rham
Immunology and Transplant Unit, Division of Immunology and Allergology and Division of Laboratory Medicine, Geneva University Hospital and Medical School, Switzerland
These authors contributed equally to this work.
Search for more papers by this authorDiderik Tirefort
Laboratory of Experimental Cell Therapy, Department of Genetic and Laboratory Medicine, Geneva University Hospital, Switzerland
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Switzerland
Search for more papers by this authorSylvie Ferrari-Lacraz
Immunology and Transplant Unit, Division of Immunology and Allergology and Division of Laboratory Medicine, Geneva University Hospital and Medical School, Switzerland
Search for more papers by this authorKarl-Heinz Krause
Laboratory of Experimental Cell Therapy, Department of Genetic and Laboratory Medicine, Geneva University Hospital, Switzerland
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Switzerland
Search for more papers by this authorCorresponding Author
Jean Villard
Immunology and Transplant Unit, Division of Immunology and Allergology and Division of Laboratory Medicine, Geneva University Hospital and Medical School, Switzerland
Correspondence to: Jean VILLARD, M.D., Ph.D., Immunology and Transplant Unit, Geneva University Hospital and Medical School, 24, rue Micheli-du-Crest 1211 Geneva 14, Switzerland.Tel.: +4122 3729394Fax: +4122 3729390E-mail: [email protected]Search for more papers by this authorOlivier Preynat-Seauve
Laboratory of Experimental Cell Therapy, Department of Genetic and Laboratory Medicine, Geneva University Hospital, Switzerland
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Switzerland
These authors contributed equally to this work.
Search for more papers by this authorCasimir de Rham
Immunology and Transplant Unit, Division of Immunology and Allergology and Division of Laboratory Medicine, Geneva University Hospital and Medical School, Switzerland
These authors contributed equally to this work.
Search for more papers by this authorDiderik Tirefort
Laboratory of Experimental Cell Therapy, Department of Genetic and Laboratory Medicine, Geneva University Hospital, Switzerland
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Switzerland
Search for more papers by this authorSylvie Ferrari-Lacraz
Immunology and Transplant Unit, Division of Immunology and Allergology and Division of Laboratory Medicine, Geneva University Hospital and Medical School, Switzerland
Search for more papers by this authorKarl-Heinz Krause
Laboratory of Experimental Cell Therapy, Department of Genetic and Laboratory Medicine, Geneva University Hospital, Switzerland
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Switzerland
Search for more papers by this authorCorresponding Author
Jean Villard
Immunology and Transplant Unit, Division of Immunology and Allergology and Division of Laboratory Medicine, Geneva University Hospital and Medical School, Switzerland
Correspondence to: Jean VILLARD, M.D., Ph.D., Immunology and Transplant Unit, Geneva University Hospital and Medical School, 24, rue Micheli-du-Crest 1211 Geneva 14, Switzerland.Tel.: +4122 3729394Fax: +4122 3729390E-mail: [email protected]Search for more papers by this authorAbstract
Neural progenitor cells (NPC) of foetal origin or derived from human embryonic stem cells (HESC) have the potential to differentiate into mature neurons after transplantation into the central nervous system, opening the possibility of cell therapy for neurodegenerative disorders. In most cases, the transplanted NPC are genetically unrelated to the recipient, leading to potential rejection of the transplanted cells. Very few data provide reliable information as to the potential immune response of allogeneic neural progenitors derived from HESC. In this study, we analyzed in vitro the allogeneic immune response of T lymphocytes and natural killer (NK) cells to NPC derived from HESC or of foetal origin. We demonstrate that NPC induce T-cell stimulation and a strong NK cytotoxic response. NK-cell activity is unrelated to MHC-I expression but driven by the activating NKG2D receptor. Cyclosporine and dexamethasone previously used in clinical studies with foetal NPC did not only fail to prevent NK alloreactivity but strongly inhibited the terminal maturation from NPC into mature neurons. We conclude that allogenic transplantation of NPC in the central nervous system will most likely require an immunosuppressive regimen targeting allogenic T and NK cells, whereas possible interference with the differentiation of NPC needs to be carefully evaluated.
References
- 1 Morizane A, Li JY, Brundin P. From bench to bed: the potential of stem cells for the treatment of Parkinson’s disease. Cell Tissue Res. 2008; 331: 323–36.
- 2 Grinnemo KH, Kumagai-Braesch M, Mansson-Broberg A, et al . Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. Reprod Biomed Online. 2006; 13: 712–24.
- 3 Drukker M, Katz G, Urbach A, et al . Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA. 2002; 99: 9864–9.
- 4 Odeberg J, Piao JH, Samuelsson EB, et al . Low immunogenicity of in vitro-expanded human neural cells despite high MHC expression. J Neuroimmunol. 2005; 161: 1–11.
- 5 Li L, Baroja ML, Majumdar A, et al . Human embryonic stem cells possess immune-privileged properties. Stem Cells. 2004; 22: 448–56.
- 6 Lanier LL. NK cell recognition. Annu Rev Immunol. 2005; 23: 225–274.
- 7 Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005; 5: 201–214.
- 8 Bashirova AA, Martin MP, McVicar DW, et al . The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006; 7: 277–300.
- 9 Drukker M. Immunogenicity of embryonic stem cells and their progeny. Methods Enzymol. 2006; 420: 391–409.
- 10 Spencer DD, Robbins RJ, Naftolin F, et al . Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson’s disease. N Engl J Med. 1992; 327: 1541–48.
- 11 Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson’s disease: how can we make it work? Trends Neurosci. 2005; 28: 86–92.
- 12 Preynat-Seauve O, Suter DM, Tirefort D, et al . Development of human nervous tissue upon differentiation of embryonic stem cells in three dimensional culture. Stem Cells. 2009; 27: 509–20.
- 13 Kraus AB, Shaffer J, Toh HC, et al . Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol. 2003; 31: 609–21.
- 14 Uhrberg M. The CD107 mobilization assay: viable isolation and immunotherapeutic potential of tumor-cytolytic NK cells. Leukemia 2005; 19: 707–9.
- 15 Kaufman DB, Shapiro R, Lucey MR, et al . Immunosuppression: practice and trends. Am J Transplant. 2004; 4: 38–53.
- 16 Barbari AG, Masri MA, Stephan AG, et al . Cyclosporine lymphocyte maximum level: a new alternative for cyclosporine monitoring in kidney transplantation. Exp Clin Transplant. 2005; 3: 293–300.
- 17 Donato R, Miljan EA, Hines SJ, et al . Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci. 2007; 8: 36.
- 18 Hoffrogge R, Mikkat S, Scharf C, et al . 2-DE proteome analysis of a proliferating and differentiating human neuronal stem cell line (ReNcell VM). Proteomics. 2006; 6: 1833–47.
- 19 Newman MB, Bakay RA. Therapeutic potentials of human embryonic stem cells in Parkinson’s disease. Neurotherapeutics. 2008; 5: 237–51.
- 20 Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell. 2008; 132: 567–582.
- 21 Rogers NJ, Lechler RI. Allorecognition. Am J Transplant. 2001; 1: 97–102.
- 22 Villard J. Immunity after organ transplantation. Swiss Med Wkly. 2006; 136: 71–7.
- 23 Ruggeri L, Capanni M, Urbani E, et al . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295: 2097–100.
- 24 Ruggeri L, Mancusi A, Capanni M, et al . Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007; 110: 433–40.
- 25 Vilches C, Parham P. Do NK-cell receptors and alloreactivity affect solid organ transplantation? Transpl Immunol. 2006; 17: 27–30.
- 26 Moretta A, Bottino C, Vitale M, et al . Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001: 19; 197–223.
- 27 Moretta L, Bottino C, Pende D, et al . Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett. 2005; 100: 7–13.
- 28 Dressel R, Schindehutte J, Kuhlmann T, et al . The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients’ immune response. PLoS ONE. 2008; 3: e2622.
- 29 Simpson E. A historical perspective on immunological privilege. Immunol Rev. 2006; 213: 12–22.
- 30 Mason DW, Charlton HM, Jones AJ, et al . The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents. Neuroscience. 1986; 19: 685–94.
- 31 Widner H, Brundin P. Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Res. 1988; 472: 287–324.
- 32 Moynihan JA, Santiago FM. Brain behavior and immunity: twenty years of T cells. Brain Behav Immun. 2007; 21: 872–80.
- 33 Segal BM. The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol. 2007; 191: 2–7.
- 34 Olanow CW, Goetz CG, Kordower JH, et al . A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol. 2003; 54: 403–14.
- 35 Freed CR, Greene PE, Breeze RE, et al . Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med. 2001; 344: 710–9.
- 36 Chiossone L, Vitale C, Cottalasso F, et al . Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood. 2007; 109: 3767–75.
- 37 Wang H, Grzywacz B, Sukovich D, et al . The unexpected effect of cyclosporin A on CD56+. Blood. 2007; 110: 1530–9.
- 38 Wai LE, Fujiki M, Takeda S, et al . Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation. 2008; 85: 145–9.
- 39 Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med. 2005; 353: 1711–23.
- 40 Liu J, Farmer JD, Lane WS, et al . Calcineurin is a common target of cyclophillin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991; 66: 807–15.
- 41 Nahreini P, Hovland AR, Kumar B, et al . Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells. Cell Mol Neurobiol. 2001; 21: 65–79.
- 42 Chiu R, Rey O, Zheng JQ, et al . Effects of altered expression and localization of cyclophilin A on differentiation of p19 embryonic carcinoma cells. Cell Mol Neurobiol. 2003; 23: 929–43.
- 43 Suter DM, Krause KH. Neural commitment of embryonic stem cells: molecules, pathways and potential for cell therapy. J Pathol. 2008; 215: 355–68.
- 44 Irons H, Lind JG, Wakade CG, et al . Intracerebral xenotransplantation of GFP mouse bone marrow stromal cells in intact and stroke rat brain: graft survival and immunologic response Cell Transplant. 2004; 13: 283–94.
Citing Literature
